These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31362918)

  • 21. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis.
    Yang SS; Cai CW; Ma XQ; Xu J; Yu CB
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):507-514. PubMed ID: 33051132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
    Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of chronic hepatitis B in india: what is the cost of life?
    Anand AC
    Natl Med J India; 2002; 15(6):317-9. PubMed ID: 12540063
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
    Wang GL; Liu Y; Qiu P; Zhou SF; Xu LF; Wen P; Wen JB; Xiao XZ
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):866-72. PubMed ID: 27010143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Economic evaluation of antiviral treatment for chronic hepatitis B: a systematic review].
    Solari L; Hijar G; Zavala R; Ureta JM
    Rev Peru Med Exp Salud Publica; 2010 Mar; 27(1):68-79. PubMed ID: 21072453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
    Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG
    Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan.
    Pwu RF; Chan KA
    J Formos Med Assoc; 2002 Sep; 101(9):632-41. PubMed ID: 12645191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Nagral A
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929871
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.
    Buti M; Casado MA; Calleja JL; Salmerón J; Aguilar J; Rueda M; Esteban R
    Aliment Pharmacol Ther; 2006 Feb; 23(3):409-19. PubMed ID: 16423000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effective pharmacologic therapies to treat chronic hepatitis B: how far have we really come?
    Holbrook ML
    J Manag Care Pharm; 2008; 14(1):65-9. PubMed ID: 18240884
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
    Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
    Larry L; Lu XZ; Alison T
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):431-6. PubMed ID: 17594808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
    Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
    Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland.
    Orlewska E
    Value Health; 2002; 5(5):405-21. PubMed ID: 12201858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B.
    Oyagüez I; Buti M; Brosa M; Rueda M; Casado MA
    Ann Hepatol; 2017; 16(3):358-365. PubMed ID: 28425405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 39. Telbivudine for the treatment of chronic hepatitis B infection.
    Hartwell D; Jones J; Harris P; Cooper K
    Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the benefits and costs of new therapies for hepatitis B virus infection.
    Owens DK; Black M
    Ann Intern Med; 2005 May; 142(10):863-4. PubMed ID: 15897538
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.